XFOR vs XNCR

X4 Pharmaceuticals, Inc. vs Xencor, Inc. — Valuation Comparison 2026

XFOR

Biotechnology
X4 Pharmaceuticals, Inc.
Quality
5.1
out of 10
Value Trap
49
WARN
Price
$4.14
Last close
Models
11/13
Active
VS

XNCR

Biotechnology
Xencor, Inc.
Quality
6.1
out of 10
Value Trap
15
SAFE
Price
$11.97
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType XFOR Fair ValueXFOR Upside XNCR Fair ValueXNCR Upside
Bayesian DCF Intrinsic $2.03 -51.0% $1.41 -88.2%
Earnings Power Value Intrinsic $3.32 -20.8%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.40 -90.4% $0.99 -91.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for XFOR vs XNCR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XFOR vs XNCR — Which Stock Is More Undervalued?

XNCR scores higher with a 6.1/10 quality rating vs XFOR's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing X4 Pharmaceuticals, Inc. (XFOR) and Xencor, Inc. (XNCR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XFOR currently trades at $4.14 with a QOC of 5.1/10, while XNCR trades at $11.97 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).